Roberta Dagilienė – Biomapas Academy Alumni

How did you decide to participate in the Biomapas Academy?

When I used to walk past a pharmacy every day, I could never stop dreaming about being able to help people and develop innovative pharmaceuticals. So while studying biomedical sciences, I became interested in the drug development paths, which led me to medicinal chemistry. And one day at the university, I saw a poster about the Biomapas Academy, which could help me understand what, how, where, and when happens to pharmaceutical products during the whole journey to reach us, so I signed up for it without hesitation. Even though I am usually not a lucky person, I was selected to be one of the participants, which surprised me!

How was your experience regarding the Academy?

During the few months, I deepened my existing knowledge of drug development stages and expanded it to learn more about drug regulation and pharmacovigilance. After graduating from the Academy, I got the opportunity to try out regulatory affairs as part of Biomapas – I completed a summer internship in the Regulatory Affairs department.

 

How do you feel after graduating from the Academy?

I will never forget this practice in my life, not only because it fulfilled what I was looking for, but it let me realize that I want to return to this company after my graduation and put my accumulated knowledge to use. Thanks again to all Biomapas staff for their insights and advice, and I hope to see you soon.

Biomapas Academy

What is Clinical Research? Regulatory Affairs? Pharmacovigilance?

Lina Radvilaitė – Biomapas Academy Alumni

Lina Radvilaitė – Biomapas Academy Alumni

At the time, I had already finished my Bioengineering studies, but I was continuing them in the Medical Biology field. As for quite some time Biomapas has been stuck in my mind as a prestigious company in the life sciences industry, I would visit their website or...

read more

Recent Insights

Learn from Biomapas' experts and let us know what you'd like to hear about!

Challenges in early phase oncology trials
Clinical Trials Regulation
Challenges in early phase oncology trials